Drugs / RVX-sCPD9
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07703475 | Aug 2026 → Nov 2027 expected | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RVX-sCPD9 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07703475 ↗ |
| Modality | Vaccine | “live-attenuated SARS-CoV-2 vaccine candidate” NCT07703475 ↗ |
| Route | Intranasal | “for intranasal administration” NCT07703475 ↗ |